and GCGR activation increases hepatic glucose output (balanced by incretin-mediated insulin), promotes energy expenditure through thermogenesis, and enhances hepatic fat oxidation
In the case of a GLP-1 receptor agonist like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), microdosing refers to taking lower than the labeled dose
Some people successfully transition to lifestyle-only maintenance, but it requires strong habits built during treatment
Women over 40 with a BMI of 27 or higher Those who have tried diet and exercise without sustained success Women experiencing perimenopausal or menopausal weight gain Those with weight related health conditions like prediabetes, type 2 diabetes, high blood pressure, or high cholesterol Women seeking significant rather than modest weight loss Those willing to commit to weekly injections for an extended period Women who can maintain adequate protein intake despite reduced appetite Certain conditions require caution or may preclude use
Import regulations vary by country, so domestic purchasing is generally simpler for regulatory compliance
Side effects by dose level Note: These are approximate rates from clinical trials
